Compare · EW vs INGN
EW vs INGN
Side-by-side comparison of Edwards Lifesciences Corporation (EW) and Inogen Inc (INGN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both EW and INGN operate in Industrial Specialties (Health Care), so they compete in similar markets.
- EW is the larger of the two at $50.07B, about 282.8x INGN ($177.1M).
- Over the past year, EW is up 14.7% and INGN is down 7.6% - EW leads by 22.3 points.
- INGN has been more active in the news (10 items in the past 4 weeks vs 4 for EW).
- EW has more recent analyst coverage (25 ratings vs 11 for INGN).
- Company
- Edwards Lifesciences Corporation
- Inogen Inc
- Price
- $86.97+1.29%
- $6.52+1.40%
- Market cap
- $50.07B
- $177.1M
- 1M return
- +4.52%
- +1.80%
- 1Y return
- +14.66%
- -7.65%
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NYSE
- NASDAQ
- IPO
- 2014
- News (4w)
- 4
- 10
- Recent ratings
- 25
- 11
Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral regurgitation, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products, oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Inogen Inc
Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a single source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Inogen Tidal Assist Ventilators, as well as related accessories. The company also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California.
Latest EW
- CEO Zovighian Bernard J sold $45,982 worth of shares (523 units at $87.92) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 11-K filed by Edwards Lifesciences Corporation
- SEC Form 11-K filed by Edwards Lifesciences Corporation
- SEC Form 3 filed by new insider Mistras Theodora
- SVP, Corporate Controller Dahl Andrew M. sold $48,853 worth of shares (568 units at $86.08), decreasing direct ownership by 4% to 15,334 units (SEC Form 4)
- CVP,Strategy/Corp Development Bobo Donald E Jr sold $2,000,193 worth of shares (23,145 units at $86.42) (SEC Form 4)
- SEC Form SD filed by Edwards Lifesciences Corporation
- CVP, TMTT & Surgical Chopra Daveen sold $126,905 worth of shares (1,500 units at $84.60), decreasing direct ownership by 3% to 44,324 units (SEC Form 4)
- CVP, TAVR Lippis Daniel J. exercised 620 shares at a strike of $72.68 and sold $50,307 worth of shares (620 units at $81.14) as part of a pre-agreed trading plan (SEC Form 4)
- CVP,Strategy/Corp Development Bobo Donald E Jr sold $1,472,678 worth of shares (17,968 units at $81.96), decreasing direct ownership by 30% to 22,798 units (SEC Form 4)
Latest INGN
- SEC Form S-8 filed by Inogen Inc
- Director Sahney Mira Kirti was granted 28,081 shares, increasing direct ownership by 71% to 67,805 units (SEC Form 4)
- Director Jamali Vafa was granted 28,081 shares, increasing direct ownership by 187% to 43,081 units (SEC Form 4)
- Director Boehnlein Glenn S was granted 28,081 shares, increasing direct ownership by 37% to 104,966 units (SEC Form 4)
- Director Rider Heather D. was granted 28,081 shares, increasing direct ownership by 32% to 116,282 units (SEC Form 4)
- Director Mora Elizabeth was granted 28,081 shares, increasing direct ownership by 35% to 107,261 units (SEC Form 4)
- Director Ladone Mary Kay was granted 28,081 shares, increasing direct ownership by 37% to 104,966 units (SEC Form 4)
- Director King Kevin M was granted 28,081 shares, increasing direct ownership by 37% to 104,966 units (SEC Form 4)
- New insider Jamali Vafa claimed ownership of 15,000 shares (SEC Form 3)
- EVP Entrprs Enblmnt, Ch HR Off Yi Boyer Jennifer M sold $70,313 worth of shares (10,770 units at $6.53) as part of a pre-agreed trading plan, decreasing direct ownership by 40% to 15,977 units (SEC Form 4)